GlassScriptPhysician profile
Susan H Wasserman
NPI 1073589438
$1,685.09
in general payments reported to CMS, 2019-2025
21 companies · $680 in 2025
The $680 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $608 · 2021: $11.87 · 2022: $64.89 · 2023: $219 · 2024: $102 · 2025: $680.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,000.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $193.50 | 2019-2025 | Freestyle Libre 3 |
| Beta Bionics, INC. | $182.20 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amgen INC. | $179.63 | 2019-2025 | Evenity |
| Novo Nordisk INC | $145.05 | 2019-2025 | Rybelsus, Ozempic |
| Medtronic Minimed, INC. | $125.00 | 2019 | |
| Mannkind Corporation | $125.00 | 2023 | V-Go |
| Echosens North America, INC. | $120.62 | 2025 | Fibroscan |
| Astrazeneca Pharmaceuticals LP | $116.75 | 2019 | |
| Sanofi-Aventis U.S. LLC | $100.04 | 2019 | |
| Insulet Corporation | $80.25 | 2019-2024 | Omnipod |
| Abbvie INC. | $77.67 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $40.11 | 2025 | Austedo Xr |
| Tandem Diabetes Care, INC. | $38.85 | 2021-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Merck Sharp & Dohme LLC | $36.72 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.46 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.06 | 2019 | |
| Amneal Pharmaceuticals LLC | $18.31 | 2022 | |
| Cequr Corporation | $17.52 | 2023 | Cequr Simplicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.14 | 2023 | Synjardy |
| Shire North American Group INC | $13.52 | 2019 | |
| Lilly USA, LLC | $12.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Wasserman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.